U.S. markets close in 5 hours 44 minutes

Sartorius Stedim Biotech S.A. (56S1.DE)

XETRA - XETRA Precio retrasado. Moneda en EUR.
Añadir a la lista de seguimiento
157.400.00 (0.00%)
A partir del 05:35PM CEST. Mercado abierto.

Sartorius Stedim Biotech S.A.

Zone Industrielle Les Paluds
Avenue de Jouques – CS 91051 Cedex
Aubagne 13781
France
33 4 42 84 56 00
https://www.sartorius.com

Sector(es)Healthcare
IndustriaMedical Instruments & Supplies
Empleados a tiempo completo10,493

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Rene FaberCEO & DIrector540kN/D1975
Mr. Rainer LehmannCFO & Member of Executive BoardN/DN/D1975
Ms. Petra MullerHead of Investor RelationsN/DN/DN/D
Ms. Petra KirchhoffHead of Corporate Communications & IRN/DN/D1969
Olivier GuitardHead of Controlling BPSN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Gestión corporativa

La calificación ISS Governance QuickScore de Sartorius Stedim Biotech S.A. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.